Silence Therapeutics (SLN) Shares Outstanding (2018 - 2026)

Silence Therapeutics has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $5.7 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) changed 0.02% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (changed 0.02% YoY) and the FY2025 annual result came in at $5.7 million, up 2.12% from the prior year.
• Shares Outstanding (Entity) was little changed at $5.7 million in Q1 2026 per SLN's latest filing, from $5.7 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $5.7 million in Q1 2026 and troughed at $3.9 million in Q4 2022.
• A 5-year average of $5.3 million and a median of $5.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) increased 24.69% in 2024, then rose 0.02% in 2026.
• Over 5 years, Shares Outstanding (Entity) stood at $3.9 million in 2022, then climbed by 15.21% to $4.5 million in 2023, then grew by 24.69% to $5.6 million in 2024, then grew by 2.12% to $5.7 million in 2025, then advanced by 0.01% to $5.7 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $5.7 million, $5.7 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.